Join the free virtual seminar at 7pm on Wednesday, November 17th exploring the Amgen Discover Team’s journey for a breakthrough drug in the treatment of cancer hosted by Drew’s Research Institute for Scientists Emeriti (RISE). Register at drew.edu/heroes.
KRAS is one of the most frequently mutated oncogenes in human cancer. For three decades, research approaches targeting KRAS-mutant cancers have largely failed and KRAS was considered an “undruggable” target. The Amgen team has succeeded in targeting a specific mutant, G12C, that is found in 14% of lung cancer patients using a first in class covalent inhibitor. Dr. Brian Lanman will present a one-hour seminar describing their outstanding research effort to discover LUMAKRAS (sotorasib).
Heroes in Drug Discovery Award Heroes in Drug Discovery Award is given to celebrate scientists who have made significant contributions to human healthcare.Through the award these individuals are celebrated and connected to the best and brightest science undergraduates whose passions, interests, and drive position them to be the next leaders in science research.
This event is supported by a grant from Pfizer and administered by The Independent Colleges and Universities of New Jersey, a New Jersey Nonprofit Corporation.